II. Indications
- See Angiotensin Receptor Blocker
- Hypertension
- Cardiovascular Secondary Prevention
III. Contraindications
IV. Mechanism
V. Dosing: Adults
- Swallow whole tablets (do not break or crush)
-
Hypertension or cardiovascular secondary prevention
- Start 40 mg orally daily
- Maximum 80 mg/day
VI. Adverse Effects
VII. Safety
- See Angiotensin Receptor Blocker
- Pregnancy Category X
- Unknown Safety in Lactation
IX. Resources
X. References
- (2018) Presc Lett, Resource #340901, Angiotensin Receptor Blocker (ARB) Antihypertensive Dose Comparison
- (2020) Med Lett Drugs Ther 62(1598): 73-80
- Olson (2020) Clinical Pharmacology, Medmaster Miami, p. 66-7
- Hamilton (2020) Tarascon Pocket Pharmacopoeia
Images: Related links to external sites (from Bing)
Related Studies
| telmisartan (on 4/19/2023 at Medicaid.Gov Survey of pharmacy drug pricing) | ||
| TELMISARTAN 20 MG TABLET | Generic | $0.19 each |
| TELMISARTAN 40 MG TABLET | Generic | $0.26 each |
| TELMISARTAN 80 MG TABLET | Generic | $0.28 each |
| TELMISARTAN-AMLODIPINE 40-10 | Generic | $3.72 each |
| TELMISARTAN-AMLODIPINE 40-5 MG | Generic | $3.89 each |
| TELMISARTAN-AMLODIPINE 80-10 | Generic | $2.50 each |
| TELMISARTAN-AMLODIPINE 80-5 MG | Generic | $3.05 each |
| TELMISARTAN-HYDROCHLOROTHIAZIDE 40-12.5 MG TB | Generic | $0.66 each |
| TELMISARTAN-HYDROCHLOROTHIAZIDE 80-12.5 MG TB | Generic | $0.86 each |
| TELMISARTAN-HYDROCHLOROTHIAZIDE 80-25 MG TAB | Generic | $0.79 each |
| micardis (on 1/10/2022 at Medicaid.Gov Survey of pharmacy drug pricing) | ||
| MICARDIS 80 MG TABLET | Generic | $0.28 each |
Ontology: telmisartan (C0248719)
| Definition (NCI) | A benzimidazole derivative and a non-peptide angiotensin II receptor antagonist with antihypertensive property. Telmisartan selectively antagonizes angiotensin II binding to the AT1 subtype receptor, located in vascular smooth muscle and adrenal gland. The antagonism results in vasodilation and inhibits the angiotensin II-mediated aldosterone production, which in turn leading to a decrease in sodium and water as well as an increase in potassium excretion leading to a subsequent reduction in blood pressure. |
| Concepts | Pharmacologic Substance (T121) , Organic Chemical (T109) |
| MSH | C084178 |
| SnomedCT | 318985000, 129487008, 387069000 |
| LNC | LP171643-2 |
| English | (1,1'-Biphenyl)-2-carboxylic acid, 4'-((1,4'-dimethyl-2'-propyl(2,6'-bi-1H-benzimidazol)-1'-yl)methyl)-, 4'-((1,4'-dimethyl-2'-propyl(2,6'-bi-1H-benzimidazol)-1'-yl)methyl)-(1,1'-biphenyl)-2-carboxylic acid, 4'-((4-Methyl-6-(1-methyl-2-benzimidazolyl)-2-propyl-1-benzimidazolyl)methyl)-2-biphenylcarboxylic Acid, (1,1'-Biphenyl)-2-carboxylic Acid, 4'-((1,4'-dimethyl-2'-propyl(2,6'-bi-1H-benzimidazol)-1'-yl)methyl)-, telmisartan (medication), telmisartan, telmisartan [Chemical/Ingredient], TELMISARTAN, Telmisartan (product), Telmisartan (substance), Telmisartan |
| Spanish | telmisartano (sustancia), telmisartano, telmisartán (producto), telmisartán (sustancia), telmisartán |
Ontology: Micardis (C0721704)
| Concepts | Pharmacologic Substance (T121) , Organic Chemical (T109) |
| MSH | C084178 |
| English | Micardis, telmisartan (Micardis), micardis, Boehringer Ingelheim brand of telmisartan, Abbott brand of telmisartan |
